BIG1 Antibody

Molecular Function of BIG1 Protein

BIG1 (ARFGEF1) promotes guanine nucleotide exchange on ARF1/ARF3, activating these GTPases by replacing GDP with GTP . Key roles include:

• Vesicular trafficking: Mediates cargo transport between Golgi and plasma membrane .

• Golgi integrity: Maintains Golgi structure independently of its GTPase-activating function .

• Integrin maturation: Required for glycosylation and maturation of integrin β1 in the Golgi .

• Nuclear functions: Associates with nucleoporins and nucleolin in nuclear transport and matrix organization .

Key Technical Data

Golgi and Integrin Regulation

• Depleting BIG1 via siRNA disrupts Golgi structure, leading to fragmented membranes and impaired integrin β1 glycosylation .

• Aberrant β1 fails to support cell adhesion or migration, reducing HepG2 cell attachment to collagen I by 36% .

Inflammatory Response Modulation

• Myeloid-specific BIG1 knockout (cKO) mice show:

  • 40% reduction in mortality from LPS-induced sepsis .

  • 50–70% decrease in serum TNF-α, IL-6, and IL-1β levels .

Nuclear Localization

• Serum starvation triggers BIG1 nuclear translocation, where it interacts with nucleoporin p62 and nucleolin .

• Nuclear BIG1 lacks ARF-binding activity, suggesting distinct roles from cytosolic/Golgi-associated forms .

Clinical Implications

• Sepsis: BIG1 inhibition reduces hyperinflammation, positioning it as a therapeutic target .

• Cancer: Altered BIG1 expression correlates with impaired integrin-mediated adhesion and metastasis .

Limitations and Future Directions

• Off-target effects: Commercial BIG1 antibodies (e.g., ab72061) detect non-specific bands at 31/41 kDa .

• Therapeutic potential: No clinical-stage BIG1-targeting antibodies exist, but lessons from brain-penetrating sdAbs (e.g., C-C7) could guide delivery strategies.